Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Alex Sparreboom
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Concepts & Ideas
Procedures
Sign-in to see full Profile
Network (preview)
140
Verweij, Jaap
63
Figg, William
59
Loos, Walter
42
Nooter, Kees
38
Stoter, Gerrit
37
de Jonge, M J A
34
de Bruijn, Peter
32
Mathijssen, Ron
29
Baker, Sharyn
20
Gelderblom, Hans
19
Brouwer, E
17
Planting, A S T
14
van der Burg, M E L
14
de Jong, Floris
12
ten Tije, Albert
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Alex Sparreboom (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Hu Shuiying; Chen Zhaoyuan; Franke Ryan; Orwick Shelley; Zhao Ming; Rudek Michelle A; Sparreboom Alex; Baker Sharyn D
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6062-9.
-
2009: Filipski K K; Mathijssen R H; Mikkelsen T S; Schinkel A H; Sparreboom A
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.
Clinical pharmacology and therapeutics 2009;86(4):396-402.
-
2009: Franke Ryan M; Scherkenbach Lisa A; Sparreboom Alex
Pharmacogenetics of the organic anion transporting polypeptide 1A2.
Pharmacogenomics 2009;10(3):339-44.
-
2009: Sparreboom A; Verweij J
Advances in cancer therapeutics.
Clinical pharmacology and therapeutics 2009;85(2):113-7.
-
2009: Baker S D; Verweij J; Cusatis G A; van Schaik R H; Marsh S; Orwick S J; Franke R M; Hu S; Schuetz E G; Lamba V; Messersmith W A; Wolff A C; Carducci M A; Sparreboom A
Pharmacogenetic pathway analysis of docetaxel elimination.
Clinical pharmacology and therapeutics 2009;85(2):155-63.
-
2009: Mathijssen R H J; Sparreboom A
Influence of lean body weight on anticancer drug clearance.
Clinical pharmacology and therapeutics 2009;85(1):23; author reply 24.
-
2009: Gardner Erin R; Smith Nicola F; Figg William D; Sparreboom Alex
Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
Journal of experimental & clinical cancer research : CR 2009;28():99.
-
2008: Franke R M; Baker S D; Mathijssen R H; Schuetz E G; Sparreboom A
Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.
Clinical pharmacology and therapeutics 2008;84(6):704-9.
-
2008: Franke Ryan M; Sparreboom Alex
Inhibition of imatinib transport by uremic toxins during renal failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4226-7; author reply 4227-8.
-
2008: de Jong F A; Verweij J; Sparreboom A
Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patients.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18(5):1152.
-
2008: Cusatis George; Sparreboom Alex
Pharmacogenomic importance of ABCG2.
Pharmacogenomics 2008;9(8):1005-9.
-
2008: de Jong F A; van der Bol J M; Mathijssen R H J; van Gelder T; Wiemer E A C; Sparreboom A; Verweij J
Renal function as a predictor of irinotecan-induced neutropenia.
Clinical pharmacology and therapeutics 2008;84(2):254-62.
-
2008: Sissung Tristan M; Baum Caitlin E; Deeken John; Price Douglas K; Aragon-Ching Jeanny; Steinberg Seth M; Dahut William; Sparreboom Alex; Figg William D
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(14):4543-9.
-
2008: Gardner Erin R; Dahut William L; Scripture Charity D; Jones Jacquin; Aragon-Ching Jeanny B; Desai Neil; Hawkins Michael J; Sparreboom Alex; Figg William D
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(13):4200-5.
-
2008: Filipski Kelly K; Loos Walter J; Verweij Jaap; Sparreboom Alex
Interaction of Cisplatin with the human organic cation transporter 2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3875-80.
-
2008: Hamada Akinobu; Sissung Tristan; Price Douglas K; Danesi Romano; Chau Cindy H; Sharifi Nima; Venzon David; Maeda Kenji; Nagao Keisuke; Sparreboom Alex; Mitsuya Hiroaki; Dahut William L; Figg William D
Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3312-8.
-
2008: Hu Shuiying; Franke Ryan M; Filipski Kelly K; Hu Chaoxin; Orwick Shelley J; de Bruijn Ernst A; Burger Herman; Baker Sharyn D; Sparreboom Alex
Interaction of imatinib with human organic ion carriers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(10):3141-8.
-
2008: Smith N F; Baker S D; Gonzalez F J; Harris J W; Figg W D; Sparreboom A
Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.
British journal of cancer 2008;98(10):1630-2.
-
2008: Poonkuzhali Balasubramanian; Lamba Jatinder; Strom Stephen; Sparreboom Alex; Thummel Kenneth; Watkins Paul; Schuetz Erin
Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(4):780-95.
-
2008: Chu Zyting; Chen Jen-Shi; Liau Chi-Ting; Wang Hung-Ming; Lin Yung-Chang; Yang Muh-Hwa; Chen Po-Min; Gardner Erin R; Figg William D; Sparreboom Alex
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
Anti-cancer drugs 2008;19(3):275-81.
-
2008: Gardner Erin R; Sparreboom Alex; Verweij Jaap; Figg William D
Lack of ABC transporter autoinduction in mice following long-term exposure to imatinib.
Cancer biology & therapy 2008;7(3):412-5.
-
2008: Gregorc V; Hidalgo M; Spreafico A; Cusatis G; Ludovini V; Ingersoll R G; Marsh S; Steinberg S M; Viganò M G; Ghio D; Villa E; Sparreboom A; Baker S D
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.
Clinical pharmacology and therapeutics 2008;83(3):477-84.
-
2008: de Jong Floris A; Sparreboom Alex; Verweij Jaap; Mathijssen Ron H J
Lifestyle habits as a contributor to anti-cancer treatment failure.
European journal of cancer (Oxford, England : 1990) 2008;44(3):374-82.
-
2008: Sissung Tristan M; Danesi Romano; Price Douglas K; Steinberg Seth M; de Wit Ronald; Zahid Muhammad; Gaikwad Nilesh; Cavalieri Ercole; Dahut William L; Sackett Dan L; Figg William D; Sparreboom Alex
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
Molecular cancer therapeutics 2008;7(1):19-26.
-
2008: Schrump David S; Fischette Maria R; Nguyen Dao M; Zhao Ming; Li Xinmin; Kunst Tricia F; Hancox Ana; Hong Julie A; Chen G Aaron; Kruchin Evgeny; Wright John J; Rosing Douglas R; Sparreboom Alex; Figg William D; Steinberg Seth M
Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):188-98.
-
2007: van Erp Nielka P; Gelderblom Hans; Karlsson Mats O; Li Jing; Zhao Ming; Ouwerkerk Jan; Nortier Johan W; Guchelaar Henk-Jan; Baker Sharyn D; Sparreboom Alex
Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(24):7394-400.
-
2007: Sparreboom Alex; Wolff Antonio C; Mathijssen Ron H J; Chatelut Etienne; Rowinsky Eric K; Verweij Jaap; Baker Sharyn D
Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4707-13.
-
2007: Hamada Akinobu; Danesi Romano; Price Douglas K; Sissung Tristan; Chau Cindy; Venzon David; Sparreboom Alex; Dahut William L; Figg William D
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer.
Urology 2007;70(2):217-20.
-
2007: Mathijssen Ron H J; de Jong Floris A; Loos Walter J; van der Bol Jessica M; Verweij Jaap; Sparreboom Alex
Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?
The oncologist 2007;12(8):913-23.
-
2007: Sparreboom Alex
Unexplored pharmacokinetic opportunities with microdosing in oncology.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4033-4.
-
2007: van der Bol Jessica M; Mathijssen Ron H J; Loos Walter J; Friberg Lena E; van Schaik Ron H N; de Jonge Maja J A; Planting André S Th; Verweij Jaap; Sparreboom Alex; de Jong Floris A
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2719-26.
-
2007: Lakhani Nehal J; Sparreboom Alex; Xu Xia; Veenstra Timothy D; Venitz Jürgen; Dahut William L; Figg William D
Characterization of in vitro and in vivo metabolic pathways of the investigational anticancer agent, 2-methoxyestradiol.
Journal of pharmaceutical sciences 2007;96(7):1821-31.
-
2007: Puisset F; Chatelut E; Sparreboom A; Delord J-P; Berchery D; Lochon I; Lafont T; Roché H
Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect.
Cancer chemotherapy and pharmacology 2007;60(2):305-8.
-
2007: Gojo Ivana; Jiemjit Anchalee; Trepel Jane B; Sparreboom Alex; Figg William D; Rollins Sandra; Tidwell Michael L; Greer Jacqueline; Chung Eun Joo; Lee Min-Jung; Gore Steven D; Sausville Edward A; Zwiebel James; Karp Judith E
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Blood 2007;109(7):2781-90.
-
2007: Engels Frederike K; de Jong Floris A; Sparreboom Alex; Mathot Ron A A; Loos Walter J; Kitzen Jos J E M; de Bruijn Peter; Verweij Jaap; Mathijssen Ron H J
Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.
The oncologist 2007;12(3):291-300.
-
2007: Li Jing; Cusatis George; Brahmer Julie; Sparreboom Alex; Robey Robert W; Bates Susan E; Hidalgo Manuel; Baker Sharyn D
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Cancer biology & therapy 2007;6(3):432-8.
-
2007: Deeken John F; Figg William D; Bates Susan E; Sparreboom Alex
Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics.
Anti-cancer drugs 2007;18(2):111-26.
-
2007: Smith N F; Marsh S; Scott-Horton T J; Hamada A; Mielke S; Mross K; Figg W D; Verweij J; McLeod H L; Sparreboom A
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.
Clinical pharmacology and therapeutics 2007;81(1):76-82.
-
2007: de Jong F A; Scott-Horton T J; Kroetz D L; McLeod H L; Friberg L E; Mathijssen R H; Verweij J; Marsh S; Sparreboom A
Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
Clinical pharmacology and therapeutics 2007;81(1):42-9.
-
2006: Cusatis George; Gregorc Vanesa; Li Jing; Spreafico Anna; Ingersoll Roxann G; Verweij Jaap; Ludovini Vienna; Villa Eugenio; Hidalgo Manuel; Sparreboom Alex; Baker Sharyn D
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Journal of the National Cancer Institute 2006;98(23):1739-42.
-
2006: Sissung Tristan M; Mross Klaus; Steinberg Seth M; Behringer Dirk; Figg William D; Sparreboom Alex; Mielke Stephan
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
European journal of cancer (Oxford, England : 1990) 2006;42(17):2893-6.
-
2006: de Jong Floris A; Kehrer Diederik F S; Mathijssen Ron H J; Creemers Geert-Jan; de Bruijn Peter; van Schaik Ron H N; Planting André S Th; van der Gaast Ate; Eskens Ferry A L M; Janssen Jos Th P; Ruit Jan B; Verweij Jaap; Sparreboom Alex; de Jonge Maja J A
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
The oncologist 2006;11(8):944-54.
-
2006: Lakhani Nehal; Sparreboom Alex; Venitz Jürgen; Dahut William L; Figg William D
Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
Anti-cancer drugs 2006;17(8):977-83.
-
2006: Acharya Milin R; Karp Judith E; Sausville Edward A; Hwang Kyunghwa; Ryan Qin; Gojo Ivana; Venitz Jurgen; Figg William D; Sparreboom Alex
Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.
Investigational new drugs 2006;24(5):367-75.
-
2006: Cox Michael C; Low Jennifer; Lee James; Walshe Janice; Denduluri Neelima; Berman Arlene; Permenter Matthew G; Petros William P; Price Douglas K; Figg William D; Sparreboom Alex; Swain Sandra M
Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4636-40.
-
2006: Gardner Erin R; Burger Herman; van Schaik Ron H; van Oosterom Allan T; de Bruijn Ernst A; Guetens Gunther; Prenen Hans; de Jong Floris A; Baker Sharyn D; Bates Susan E; Figg William D; Verweij Jaap; Sparreboom Alex; Nooter Kees
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Clinical pharmacology and therapeutics 2006;80(2):192-201.
-
2006: Ng Sylvia S W; Sparreboom Alex; Shaked Yuval; Lee Christina; Man Shan; Desai Neil; Soon-Shiong Patrick; Figg William D; Kerbel Robert S
Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 1):4331-8.
-
2006: Baker Sharyn D; Sparreboom Alex
Predicting vinorelbine disposition and toxicity: does BSA provide more than a "bad statistical association"?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2412-3.
-
2006: Scripture Charity D; Figg William D; Sparreboom Alex
Peripheral neuropathy induced by Paclitaxel: recent insights and future perspectives.
Current neuropharmacology 2006;4(2):165-72.
-
2006: Sparreboom Alex; Figg William D
Identifying sources of interindividual pharmacokinetic variability with population modeling.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):1951-3.
-
2006: Loos Walter J; de Jongh Felix E; Sparreboom Alex; de Wit Ronald; van Boven-van Zomeren Desiree M; Stoter Gerrit; Nooter Kees; Verweij Jaap
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1499-506.
-
2006: Sissung Tristan M; Price Douglas K; Sparreboom Alex; Figg William D
Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention.
Molecular cancer research : MCR 2006;4(3):135-50.
-
2006: Smith Nicola F; Figg William D; Sparreboom Alex
Pharmacogenetics of irinotecan metabolism and transport: an update.
Toxicology in vitro : an international journal published in association with BIBRA 2006;20(2):163-75.
-
2006: Scripture Charity D; Figg William D; Sparreboom Alex
The role of drug-metabolising enzymes in clinical responses to chemotherapy.
Expert opinion on drug metabolism & toxicology 2006;2(1):17-25.
-
2006: Acharya Milin R; Sparreboom Alex; Sausville Edward A; Conley Barbara A; Doroshow James H; Venitz Jurgen; Figg William D
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Cancer chemotherapy and pharmacology 2006;57(3):275-81.
-
2006: Dahut William L; Lakhani Nehal J; Gulley James L; Arlen Philip M; Kohn Elise C; Kotz Herbert; McNally Debbie; Parr Allyson; Nguyen Diana; Yang Sherry X; Steinberg Seth M; Venitz Jürgen; Sparreboom Alex; Figg William D
Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors.
Cancer biology & therapy 2006;5(1):22-7.
-
2006: Mielke Stephan; Sparreboom Alex; Mross Klaus
Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.
European journal of cancer (Oxford, England : 1990) 2006;42(1):24-30.
-
2006: Hwang Kyunghwa; Scripture Charity D; Gutierrez Martin; Kummar Shivaani; Figg William D; Sparreboom Alex
Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;830(1):35-40.
-
2006: Gardner Erin R; Liau Chi-Ting; Chu Zyting E; Figg William D; Sparreboom Alex
Determination of paclitaxel in human plasma following the administration of Genaxol or Genetaxyl by liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2006;20(14):2170-4.
-
2006: Baker Sharyn D; Sparreboom Alex; Verweij Jaap
Clinical pharmacokinetics of docetaxel : recent developments.
Clinical pharmacokinetics 2006;45(3):235-52.
-
2005: Mielke Stephan; Sparreboom Alex; Behringer Dirk; Mross Klaus
Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen.
Anticancer research 2005;25(6C):4423-7.
-
2005: Henningsson Anja; Marsh Sharon; Loos Walter J; Karlsson Mats O; Garsa Adam; Mross Klaus; Mielke Stephan; Viganò Lucia; Locatelli Alberta; Verweij Jaap; Sparreboom Alex; McLeod Howard L
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(22):8097-104.
-
2005: van Erp Nielka P H; Baker Sharyn D; Zhao Ming; Rudek Michelle A; Guchelaar Henk-Jan; Nortier Johan W R; Sparreboom Alex; Gelderblom Hans
Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7800-6.
-
2005: Sparreboom Alex; Baker Sharyn D; Verweij Jaap
Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):7765-7.
-
2005: Smith Nicola F; Figg William D; Sparreboom Alex
Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.
Expert opinion on drug metabolism & toxicology 2005;1(3):429-45.
-
2005: Lepper Erin R; Baker Sharyn D; Permenter Matt; Ries Nicole; van Schaik Ron H N; Schenk Paul W; Price Douglas K; Ahn Danielle; Smith Nicola F; Cusatis George; Ingersoll Roxann G; Bates Susan E; Mathijssen Ron H J; Verweij Jaap; Figg William D; Sparreboom Alex
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7398-404.
-
2005: Scripture Charity D; Sparreboom Alex; Figg William D
Modulation of cytochrome P450 activity: implications for cancer therapy.
The lancet oncology 2005;6(10):780-9.
-
2005: Posadas Edwin M; Gulley James; Arlen Philip M; Trout Alisa; Parnes Howard L; Wright John; Lee Min-Jung; Chung Eun Joo; Trepel Jane B; Sparreboom Alex; Chen Clara; Jones Elizabeth; Steinberg Seth M; Daniels Andrew; Figg William D; Dahut William L
A phase II study of perifosine in androgen independent prostate cancer.
Cancer biology & therapy 2005;4(10):1133-7.
-
2005: Acharya Milin R; Sparreboom Alex; Venitz Jürgen; Figg William D
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
Molecular pharmacology 2005;68(4):917-32.
-
2005: Smith Nicola F; Acharya Milin R; Desai Neil; Figg William D; Sparreboom Alex
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel.
Cancer biology & therapy 2005;4(8):815-8.
-
2005: Engels F K; Sparreboom A; Mathot R A A; Verweij J
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
British journal of cancer 2005;93(2):173-7.
-
2005: Mielke Stephan; Sparreboom Alex; Steinberg Seth M; Gelderblom Hans; Unger Clemens; Behringer Dirk; Mross Klaus
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4843-50.
-
2005: Burger Herman; van Tol Hans; Brok Mariël; Wiemer Erik A C; de Bruijn Ernst A; Guetens Gunther; de Boeck Gert; Sparreboom Alex; Verweij Jaap; Nooter Kees
Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.
Cancer biology & therapy 2005;4(7):747-52.
-
2005: Scripture Charity D; Figg William D; Sparreboom Alex
Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy.
Therapeutics and clinical risk management 2005;1(2):107-14.
-
2005: Sparreboom Alex
BSA-based dosing and alternative approaches.
Clinical advances in hematology & oncology : H&O 2005;3(6):448-50.
-
2005: Sparreboom Alex; Scripture Charity D; Trieu Vuong; Williams Paul J; De Tapas; Yang Andrew; Beals Bridget; Figg William D; Hawkins Michael; Desai Neil
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4136-43.
-
2005: Sparreboom Alex; Loos Walter J; Burger Herman; Sissung Tristan M; Verweij Jaap; Figg William D; Nooter Kees; Gelderblom Hans
Effect of ABCG2 genotype on the oral bioavailability of topotecan.
Cancer biology & therapy 2005;4(6):650-8.
-
2005: Ryan Qin C; Headlee Donna; Acharya Milin; Sparreboom Alex; Trepel Jane B; Ye Joseph; Figg William D; Hwang Kyunghwa; Chung Eun Joo; Murgo Anthony; Melillo Giovanni; Elsayed Yusri; Monga Manish; Kalnitskiy Mikhail; Zwiebel James; Sausville Edward A
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3912-22.
-
2005: Scripture Charity D; Szebeni Janos; Loos Walter J; Figg William D; Sparreboom Alex
Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
Cancer biology & therapy 2005;4(5):555-60.
-
2005: de Jong Floris A; Engels Frederike K; Mathijssen Ron H J; van Zuylen Lia; Verweij Jaap; Peters Remco P H; Sparreboom Alex
Medicinal cannabis in oncology practice: still a bridge too far?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2886-91.
-
2005: Zhou Qingyu; Sparreboom Alex; Tan Eng-Huat; Cheung Yin-Bun; Lee Ann; Poon Donald; Lee Edmund J D; Chowbay Balram
Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer.
British journal of clinical pharmacology 2005;59(4):415-24.
-
2005: Fuse Eiichi; Kuwabara Takashi; Sparreboom Alex; Sausville Edward A; Figg William D
Review of UCN-01 development: a lesson in the importance of clinical pharmacology.
Journal of clinical pharmacology 2005;45(4):394-403.
-
2005: Lepper Erin R; Nooter Kees; Verweij Jaap; Acharya Milin R; Figg William D; Sparreboom Alex
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2.
Pharmacogenomics 2005;6(2):115-38.
-
2005: Soepenberg Otto; Dumez Herlinde; Verweij Jaap; de Jong Floris A; de Jonge Maja J A; Thomas José; Eskens Ferry A L M; van Schaik Ron H N; Selleslach Johan; Ter Steeg Judith; Lefebvre Patricia; Assadourian Sylvie; Sanderink Ger-Jan; Sparreboom Alex; van Oosterom Allan T
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1504-11.
-
2005: Soepenberg Otto; Dumez Herlinde; Verweij Jaap; Semiond Dorothee; deJonge Maja J A; Eskens Ferry A L M; ter Steeg Judith; Selleslach Johan; Assadourian Sylvie; Sanderink Ger-Jan; Sparreboom Alex; van Oosterom A T
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):889-98.
-
2005: Soepenberg Otto; de Jonge Maja J A; Sparreboom Alex; de Bruin Peter; Eskens Ferry A L M; de Heus Gerda; Wanders Jantien; Cheverton Peter; Ducharme Murray P; Verweij Jaap
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):703-11.
-
2005: Portielje Johanna E A; Kruit Wim H J; Eerenberg Anke J M; Schuler Martin; Sparreboom Alex; Lamers Cor H J; Gratama Jan-Willem; Stoter Gerrit; Huber Christoph; Hack C Erik
Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant.
Cancer immunology, immunotherapy : CII 2005;54(1):37-43.
-
2005: Baker Sharyn D; Li Jing; ten Tije Albert J; Figg William D; Graveland Wilfried; Verweij Jaap; Sparreboom Alex
Relationship of systemic exposure to unbound docetaxel and neutropenia.
Clinical pharmacology and therapeutics 2005;77(1):43-53.
-
2005: Planting A S T; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg M E L; Luyten G P M; de Leeuw K; de Boer-Dennert M; Wissel P S; Jewell R C; Paul E M; Purvis N B; Verweij J
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;55(1):91-9.
-
2005: Lakhani Nehal J; Lepper Erin R; Sparreboom Alex; Dahut William L; Venitz Jürgen; Figg William D
Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2005;19(9):1176-82.
-
2004: Baker Sharyn D; van Schaik Ron H N; Rivory Laurent P; Ten Tije Albert J; Dinh Kimberly; Graveland Wilfried J; Schenk Paul W; Charles Kellie A; Clarke Stephen J; Carducci Michael A; McGuire William P; Dawkins Fitzroy; Gelderblom Hans; Verweij Jaap; Sparreboom Alex
Factors affecting cytochrome P-450 3A activity in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8341-50.
-
2004: Léger Frédéric; Loos Walter J; Bugat Roland; Mathijssen Ron H J; Goffinet Marine; Verweij Jaap; Sparreboom Alex; Chatelut Etienne
Mechanism-based models for topotecan-induced neutropenia.
Clinical pharmacology and therapeutics 2004;76(6):567-78.
-
2004: Mathijssen Ron H J; de Jong Floris A; van Schaik Ron H N; Lepper Erin R; Friberg Lena E; Rietveld Trinet; de Bruijn Peter; Graveland Wilfried J; Figg William D; Verweij Jaap; Sparreboom Alex
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Journal of the National Cancer Institute 2004;96(21):1585-92.
-
2004: Tohnya Tanyifor M; Hwang Kyunghwa; Lepper Erin R; Fine Howard A; Dahut William L; Venitz Jürgen; Sparreboom Alex; Figg William D
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;811(2):135-41.
-
2004: Sparreboom Alex; Chen Huachen; Acharya Milin R; Senderowicz Adrian M; Messmann Richard A; Kuwabara Takashi; Venzon David J; Murgo Anthony J; Headlee Donna; Sausville Edward A; Figg William D
Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):6840-6.
-
2004: de Jong Floris A; Marsh Sharon; Mathijssen Ron H J; King Cristi; Verweij Jaap; Sparreboom Alex; McLeod Howard L
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5889-94.
-
2004: Hwang Kyunghwa; Piekarz Richard L; Bates Susan E; Figg William D; Sparreboom Alex
Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;809(1):81-6.
-
2004: Tan Antoinette R; Yang Xiaowei; Berman Arlene; Zhai Suoping; Sparreboom Alex; Parr Allyson L; Chow Catherine; Brahim Jaime S; Steinberg Seth M; Figg William D; Swain Sandra M
Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5038-47.
-
2004: Paoluzzi Luca; Singh Arun S; Price Douglas K; Danesi Romano; Mathijssen Ron H J; Verweij Jaap; Figg William D; Sparreboom Alex
Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
Journal of clinical pharmacology 2004;44(8):854-60.
-
2004: Tan Antoinette R; Yang Xiaowei; Hewitt Stephen M; Berman Arlene; Lepper Erin R; Sparreboom Alex; Parr Allyson L; Figg William D; Chow Catherine; Steinberg Seth M; Bacharach Stephen L; Whatley Millie; Carrasquillo Jorge A; Brahim Jaime S; Ettenberg Seth A; Lipkowitz Stan; Swain Sandra M
Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3080-90.
-
2004: ten Tije Albert J; Loos Walter J; Zhao Ming; Baker Sharyn D; Enting Roelien H; van der Meulen Hans; Verweij Jaap; Sparreboom Alex
Limited cerebrospinal fluid penetration of docetaxel.
Anti-cancer drugs 2004;15(7):715-8.
-
2004: Acharya Milin R; Baker Sharyn D; Verweij Jaap; Figg William D; Sparreboom Alex
Determination of fraction unbound docetaxel using microequilibrium dialysis.
Analytical biochemistry 2004;331(1):192-4.
-
2004: de Jongh Felix E; Gallo James M; Shen Meiyu; Verweij Jaap; Sparreboom Alex
Population pharmacokinetics of cisplatin in adult cancer patients.
Cancer chemotherapy and pharmacology 2004;54(2):105-12.
-
2004: Sparreboom Alex; Marsh Sharon; Mathijssen Ron H J; Verweij Jaap; McLeod Howard L
Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.
Investigational new drugs 2004;22(3):285-9.
-
2004: Sparreboom Alex; Gelderblom Hans; Marsh Sharon; Ahluwalia Ranjeet; Obach Rosendo; Principe Paola; Twelves Chris; Verweij Jaap; McLeod Howard L
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Clinical pharmacology and therapeutics 2004;76(1):38-44.
-
2004: Lepper Erin R; Hicks J Kevin; Verweij Jaap; Zhai Suoping; Figg William D; Sparreboom Alex
Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;806(2):305-10.
-
2004: Lakhani Nehal J; Sparreboom Alex; Dahut William L; Venitz Jürgen; Figg William D
Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;806(2):289-93.
-
2004: Acharya Milin R; Venitz Jürgen; Figg William D; Sparreboom Alex
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2004;7(3):195-208.
-
2004: de Jong Floris A; Mathijssen Ron H J; Xie Rujia; Verweij Jaap; Sparreboom Alex
Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4068-71.
-
2004: Sparreboom Alex; Cox Michael C; Acharya Milin R; Figg William D
Herbal remedies in the United States: potential adverse interactions with anticancer agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2489-503.
-
2004: Tohnya Tanyifor M; Kim Sonia; Fine Howard A; Dunn Lara; Figg William D; Sparreboom Alex
Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;805(1):135-40.
-
2004: Engels Frederike K; Ten Tije Albert J; Baker Sharyn D; Lee Carlton K K; Loos Walter J; Vulto Arnold G; Verweij Jaap; Sparreboom Alex
Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Clinical pharmacology and therapeutics 2004;75(5):448-54.
-
2004: Rudek M A; Sparreboom A; Garrett-Mayer E S; Armstrong D K; Wolff A C; Verweij J; Baker S D
Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1170-8.
-
2004: Hwang Kyunghwa; Acharya Milin R; Sausville Edward A; Zhai Suoping; Woo Eunhee W; Venitz Jürgen; Figg William D; Sparreboom Alex
Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):289-94.
-
2004: de Bruijn Peter; Willems Edwin W; Loos Walter J; Verweij Jaap; Sparreboom Alex
Indirect determination of the irinotecan metabolite 7-ethyl-10-O-glucuronyl-camptothecin in human samples.
Analytical biochemistry 2004;328(1):84-6.
-
2004: Sparreboom A; Kehrer D F S; Mathijssen R H J; Xie R; de Jonge M J A; de Bruijn P; Planting A S T; Eskens F A L M; Verheij C; de Heus G; Klaren A; Zhang S; Verhaeghe T; Palmer P A; Verweij J
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
British journal of cancer 2004;90(8):1508-15.
-
2004: Baker Sharyn D; Zhao Ming; Lee Carlton K K; Verweij Jaap; Zabelina Yelena; Brahmer Julie R; Wolff Antonio C; Sparreboom Alex; Carducci Michael A
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1976-83.
-
2004: van Zuylen Lia; Bridgewater John; Sparreboom Alex; Eskens Ferry A L M; de Bruijn Peter; Sklenar Ivo; Planting Andre S T; Choi Les; Bootle Douglas; Mueller Christian; Ledermann Jonathan A; Verweij Jaap
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1949-55.
-
2004: Polee Marco B; Sparreboom Alex; Eskens Ferry A L M; Hoekstra Ronald; van de Schaaf Jacqueline; Verweij Jaap; Stoter Gerrit; van der Gaast Ate
A phase I and pharmacokinetic study of weekly paclitaxel and carboplatin in patients with metastatic esophageal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1928-34.
-
2004: Soepenberg O; Sparreboom A; de Jonge M J A; Planting A S Th; de Heus G; Loos W J; Hartman C M; Bowden C; Verweij J
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2004;40(5):681-8.
-
2004: Ng Sylvia S W; Figg William D; Sparreboom Alex
Taxane-mediated antiangiogenesis in vitro: influence of formulation vehicles and binding proteins.
Cancer research 2004;64(3):821-4.
-
2004: ten Tije A J; Smorenburg C H; Seynaeve C; Sparreboom A; Schothorst K L C; Kerkhofs L G M; van Reisen L G P M; Stoter G; Bontenbal M; Verweij J
Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial.
European journal of cancer (Oxford, England : 1990) 2004;40(3):352-7.
-
2004: Léger F; Loos W J; Fourcade J; Bugat R; Goffinet M; Mathijssen R H J; Verweij J; Sparreboom A; Chatelut E
Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.
British journal of cancer 2004;90(2):343-7.
-
2004: Baker Sharyn D; Zhao Ming; He Ping; Carducci Michael A; Verweij Jaap; Sparreboom Alex
Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry.
Analytical biochemistry 2004;324(2):276-84.
-
2004: Soepenberg Otto; de Bruijn Peter; Verweij Jaap; Atsumi Ryo; Sparreboom Alex
Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;799(1):15-22.
-
2003: Franks Michael E; Macpherson Gordon R; Lepper Erin R; Figg William D; Sparreboom Alex
New directions in cancer research 2003: technological advances in biology, drug resistance, and molecular pharmacology.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(6):301-12.
-
2003: Lakhani Nehal J; Venitz Jürgen; Figg William D; Sparreboom Alex
Pharmacogenetics of estrogen metabolism and transport in relation to cancer.
Current drug metabolism 2003;4(6):505-13.
-
2003: Ten Tije Albert J; Loos Walter J; Verweij Jaap; Baker Sharyn D; Dinh Kimberly; Figg William D; Sparreboom Alex
Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches.
Clinical pharmacology and therapeutics 2003;74(5):509-10.
-
2003: Lepper Erin R; Swain Sandra M; Tan Antoinette R; Figg William D; Sparreboom Alex
Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;796(1):181-8.
-
2003: Loos Walter J; Baker Sharyn D; Verweij Jaap; Boonstra Joke G; Sparreboom Alex
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Clinical pharmacology and therapeutics 2003;74(4):364-71.
-
2003: de Jong Floris A; Mathijssen Ron H J; de Bruijn Peter; Loos Walter J; Verweij Jaap; Sparreboom Alex
Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;795(2):383-8.
-
2003: ten Tije Albert J; Synold Timothy W; Spicer Darcy; Verweij Jaap; Doroshow James H; Sparreboom Alex
Effect of valspodar on the pharmacokinetics of unbound paclitaxel.
Investigational new drugs 2003;21(3):291-8.
-
2003: Mathijssen Ron H J; Marsh Sharon; Karlsson Mats O; Xie Rujia; Baker Sharyn D; Verweij Jaap; Sparreboom Alex; McLeod Howard L
Irinotecan pathway genotype analysis to predict pharmacokinetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3246-53.
-
2003: Ten Tije Albert J; Verweij Jaap; Sparreboom Alex; Van Der Gaast Ate; Fowst Camilla; Fiorentini Francesco; Tursi Jennifer; Antonellini Alessandro; Mantel Marijke; Hartman Carla M; Stoter Gerrit; Planting Andre S T; De Jonge Maja J A
Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):2957-64.
-
2003: Sparreboom Alex; Verweij Jaap
Paclitaxel pharmacokinetics, threshold models, and dosing strategies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(14):2803-4; author reply 2805-6.
-
2003: Gelderblom H; Loos W J; Sparreboom A; Soepenberg O; de Jonge M J A; van Boven-van Zomeren D M; Verweij J
Influence of the cisplatin hydration schedule on topotecan pharmacokinetics.
European journal of cancer (Oxford, England : 1990) 2003;39(11):1542-6.
-
2003: Gelderblom Hans; Baker Sharyn D; Zhao Ming; Verweij Jaap; Sparreboom Alex
Distribution of paclitaxel in plasma and cerebrospinal fluid.
Anti-cancer drugs 2003;14(5):365-8.
-
2003: Henningsson A; Sparreboom A; Sandström M; Freijs A; Larsson R; Bergh J; Nygren P; Karlsson M O
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1105-14.
-
2003: Sparreboom Alex; Danesi Romano; Ando Yuichi; Chan Juliana; Figg William D
Pharmacogenomics of ABC transporters and its role in cancer chemotherapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(2):71-84.
-
2003: Loos Walter J; Gelderblom Hans; Verweij Jaap; van Boven-van Zomeren Desirée M; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.
Anti-cancer drugs 2003;14(3):227-32.
-
2003: Sparreboom Alex; Wolff Antonio C; Verweij Jaap; Zabelina Yelena; van Zomeren Desiree M; McIntire Gregory L; Swindell Charles S; Donehower Ross C; Baker Sharyn D
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):151-9.
-
2003: Portielje Johanna E A; Lamers Cor H J; Kruit Wim H J; Sparreboom Alex; Bolhuis Reinder L H; Stoter Gerrit; Huber Christoph; Gratama Jan W
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):76-83.
-
2003: Smorenburg Carolien H; Sparreboom Alex; Bontenbal Marijke; Stoter Gerrit; Nooter Kees; Verweij Jaap
Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):197-202.
-
2003: Smorenburg C H; ten Tije A J; Verweij J; Bontenbal M; Mross K; van Zomeren D M; Seynaeve C; Sparreboom A
Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 2003;39(2):196-202.
-
2003: Soepenberg Otto; Sparreboom Alex; Verweij Jaap
Clinical studies of camptothecin and derivatives.
The Alkaloids. Chemistry and biology 2003;60():1-50.
-
2003: ten Tije Albert J; Verweij Jaap; Loos Walter J; Sparreboom Alex
Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
Clinical pharmacokinetics 2003;42(7):665-85.
-
2002: Baker Sharyn D; Verweij Jaap; Rowinsky Eric K; Donehower Ross C; Schellens Jan H M; Grochow Louise B; Sparreboom Alex
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.
Journal of the National Cancer Institute 2002;94(24):1883-8.
-
2002: de Jongh F E; de Wit R; Verweij J; Sparreboom A; van den Bent M J; Stoter G; van der Burg M E L
Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(15):2005-13.
-
2002: Xie Rujia; Mathijssen Ron H J; Sparreboom Alex; Verweij Jaap; Karlsson Mats O
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Clinical pharmacology and therapeutics 2002;72(3):265-75.
-
2002: Felici A; Verweij J; Sparreboom A
Dosing strategies for anticancer drugs: the good, the bad and body-surface area.
European journal of cancer (Oxford, England : 1990) 2002;38(13):1677-84.
-
2002: Mathijssen Ron H J; Verweij Jaap; de Bruijn Peter; Loos Walter J; Sparreboom Alex
Effects of St. John's wort on irinotecan metabolism.
Journal of the National Cancer Institute 2002;94(16):1247-9.
-
2002: Loos Walter J; Szebeni Janos; ten Tije Albert J; Verweij Jaap; van Zomeren Desirée M; Chung Kyu-nung; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.
Anti-cancer drugs 2002;13(7):767-75.
-
2002: Xie Rujia; Mathijssen Ron H J; Sparreboom Alex; Verweij Jaap; Karlsson Mats O
Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3293-301.
-
2002: Kehrer Diederik F S; Mathijssen Ron H J; Verweij Jaap; de Bruijn Peter; Sparreboom Alex
Modulation of irinotecan metabolism by ketoconazole.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3122-9.
-
2002: Mathijssen R H J; Verweij J; Loos W J; de Bruijn P; Nooter K; Sparreboom A
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
British journal of cancer 2002;87(2):144-50.
-
2002: Mathijssen Ron H J; Loos Walter J; Verweij Jaap; Sparreboom Alex
Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
Current cancer drug targets 2002;2(2):103-23.
-
2002: Sparreboom Alex; Zhao Ming; Brahmer Julie R; Verweij Jaap; Baker Sharyn D
Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;773(2):183-90.
-
2002: van Zuylen L; Sparreboom A; van der Gaast A; Nooter K; Eskens F A L M; Brouwer E; Bol C J; de Vries R; Palmer P A; Verweij J
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
European journal of cancer (Oxford, England : 1990) 2002;38(8):1090-9.
-
2002: Gelderblom Hans; Verweij Jaap; van Zomeren Desirée M; Buijs Dirk; Ouwens Linda; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(4):1237-41.
-
2002: de Jonge Maja J A; Punt Cornelis J A; Sparreboom Alex; Planting André S T; Peters M E W J; van De Schraaf Jacqueline; Jackman Ann; Smith Rob; de Mulder Pieter H M; Verweij Jaap
Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(7):1923-31.
-
2002: Loos Walter J; Verweij Jaap; Kehrer Diederik F S; de Bruijn Peter; de Groot Franciscus M H; Hamilton Marta; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):856-62.
-
2002: Louwerens M; Smorenburg C; Sparreboom A; Loos W J; Verweij J; de Wit R
Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(4):497-504.
-
2002: Kehrer Diederik F S; Bos Annelies M; Verweij Jaap; Groen Harry J; Loos Walter J; Sparreboom Alex; de Jonge Maja J A; Hamilton Marta; Cameron Terri; de Vries Elisabeth G E
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(5):1222-31.
-
2002: Mathijssen Ron H J; Sparreboom Alex; Dumez Herlinde; van Oosterom Allan T; de Bruijn Ernst A
Altered irinotecan metabolism in a patient receiving phenytoin.
Anti-cancer drugs 2002;13(2):139-40.
-
2002: Loos Walter J; van Zomeren Desirée M; Gelderblom Hans; Verweij Jaap; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Determination of topotecan in human whole blood and unwashed erythrocytes by high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;766(1):99-105.
-
2002: Okamoto Ryo; Takano Hiroshi; Okamura Tatsunori; Park Ji-Seon; Tanimoto Keiji; Sekikawa Takashi; Yamamoto Wataru; Sparreboom Alex; Verweij Jaap; Nishiyama Masahiko
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Japanese journal of cancer research : Gann 2002;93(1):93-102.
-
2002: Gelderblom Hans; Mross Klaus; ten Tije Albert J; Behringer Dirk; Mielke Stephan; van Zomeren Desirée M; Verweij Jaap; Sparreboom Alex
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(2):574-81.
-
2002: Mathijssen Ron H J; Verweij Jaap; de Jonge Maja J A; Nooter Kees; Stoter Gerrit; Sparreboom Alex
Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):81-7.
-
2002: Gelderblom H; Loos W J; Verweij J; van der Burg M E L; de Jonge M J A; Brouwer E; Nooter K; Stoter G; Sparreboom A
Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.
European journal of cancer (Oxford, England : 1990) 2002;38(1):205-13.
-
2002: Sparreboom A; de Jonge M J A; Verweij J
The use of oral cytotoxic and cytostatic drugs in cancer treatment.
European journal of cancer (Oxford, England : 1990) 2002;38(1):18-22.
-
2001: Smorenburg C H; Sparreboom A; Bontenbal M; Verweij J
Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
European journal of cancer (Oxford, England : 1990) 2001;37(18):2310-23.
-
2001: Gelderblom H; Sparreboom A; de Jonge M J; Loos W J; Wilms E; Mantel M A; Hennis B; Camlett I; Verweij J; van der Burg M E
Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer.
British journal of cancer 2001;85(8):1124-9.
-
2001: de Wit R; de Boer A C; vd Linden G H; Stoter G; Sparreboom A; Verweij J
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy.
British journal of cancer 2001;85(8):1099-101.
-
2001: Henningsson A; Karlsson M O; Viganò L; Gianni L; Verweij J; Sparreboom A
Mechanism-based pharmacokinetic model for paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(20):4065-73.
-
2001: Sparreboom A; Nooter K; Loos W J; Verweij J
The (ir)relevance of plasma protein binding of anticancer drugs.
The Netherlands journal of medicine 2001;59(4):196-207.
-
2001: de Jongh F E; Verweij J; Loos W J; de Wit R; de Jonge M J; Planting A S; Nooter K; Stoter G; Sparreboom A
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(17):3733-9.
-
2001: Gelderblom H; Verweij J; Nooter K; Sparreboom A
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.
European journal of cancer (Oxford, England : 1990) 2001;37(13):1590-8.
-
2001: Mathijssen R H; van Alphen R J; Verweij J; Loos W J; Nooter K; Stoter G; Sparreboom A
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2182-94.
-
2001: Yamamoto W; Verweij J; de Bruijn P; de Jonge M J; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Anti-cancer drugs 2001;12(5):419-32.
-
2001: van Zuylen L; Verweij J; Sparreboom A
Role of formulation vehicles in taxane pharmacology.
Investigational new drugs 2001;19(2):125-41.
-
2001: Kehrer D F; Sparreboom A; Verweij J; de Bruijn P; Nierop C A; van de Schraaf J; Ruijgrok E J; de Jonge M J
Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1136-41.
-
2001: van Zuylen L; Karlsson M O; Verweij J; Brouwer E; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
Cancer chemotherapy and pharmacology 2001;47(4):309-18.
-
2001: de Bruijn P; Kehrer D F; Verweij J; Sparreboom A
Liquid chromatographic determination of ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism.
Journal of chromatography. B, Biomedical sciences and applications 2001;753(2):395-400.
-
2001: Kehrer D F; Soepenberg O; Loos W J; Verweij J; Sparreboom A
Modulation of camptothecin analogs in the treatment of cancer: a review.
Anti-cancer drugs 2001;12(2):89-105.
-
2001: Eskens F A; Awada A; Cutler D L; de Jonge M J; Luyten G P; Faber M N; Statkevich P; Sparreboom A; Verweij J; Hanauske A R; Piccart M;
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1167-75.
-
2001: Portielje J E; Kruit W H; Eerenberg A J; Schuler M; Sparreboom A; Lamers C H; Bolhuis R L; Stoter G; Huber C; Hack C
Interleukin 12 induces activation of fibrinolysis and coagulation in humans.
British journal of haematology 2001;112(2):499-505.
-
2000: Loos W J; Gelderblom H J; Verweij J; Brouwer E; de Jonge M J; Sparreboom A
Gender-dependent pharmacokinetics of topotecan in adult patients.
Anti-cancer drugs 2000;11(9):673-80.
-
2000: Brouwer E; Verweij J; De Bruijn P; Loos W J; Pillay M; Buijs D; Sparreboom A
Measurement of fraction unbound paclitaxel in human plasma.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(10):1141-5.
-
2000: Gelderblom A J; Loos W J; de Jonge M J; Sparreboom A; Planting A S; van der Burg M E; Brouwer E; Verheij C; Ouwens L; Hearn S; Verweij J
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11(9):1205-7.
-
2000: Kehrer D F; Yamamoto W; Verweij J; de Jonge M J; de Bruijn P; Sparreboom A
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(9):3451-8.
-
2000: van Zuylen L; Nooter K; Sparreboom A; Verweij J
Development of multidrug-resistance convertors: sense or nonsense?
Investigational new drugs 2000;18(3):205-20.
-
2000: Loos W J; Gelderblom H; Sparreboom A; Verweij J; de Jonge M J
Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2685-9.
-
2000: van Zuylen L; Verweij J; Nooter K; Brouwer E; Stoter G; Sparreboom A
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2598-603.
-
2000: Pronk L C; Vasey P; Sparreboom A; Reigner B; Planting A S; Gordon R J; Osterwalder B; Verweij J; Twelves C
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
British journal of cancer 2000;83(1):22-9.
-
2000: van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos W J; Sparreboom A
Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
Anti-cancer drugs 2000;11(5):331-7.
-
2000: Loos W J; de Bruijn P; Verweij J; Sparreboom A
Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
Anti-cancer drugs 2000;11(5):315-24.
-
2000: de Jonge M J; Loos W J; Gelderblom H; Planting A S; van der Burg M E; Sparreboom A; Brouwer E; van Beurden V; Mantel M A; Doyle E; Hearn S; Ross G; Verweij J
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(10):2104-15.
-
2000: van Zuylen L; Sparreboom A; van der Gaast A; van der Burg M E; van Beurden V; Bol C J; Woestenborghs R; Palmer P A; Verweij J
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1365-71.
-
2000: Gelderblom H; Loos W J; Verweij J; de Jonge M J; Sparreboom A
Topotecan lacks third space sequestration.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1288-92.
-
2000: Eskens F A; Levitt N C; Sparreboom A; Choi L; Mather R; Verweij J; Harris A L
Effect of food on the pharmacokinetics of oral MMI270B (CGS 27023A), a novel matrix metalloproteinase inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):431-3.
-
2000: Loos W J; Kehrer D; Brouwer E; Verweij J; de Bruijn P; Hamilton M; Gill S; Nooter K; Stoter G; Sparreboom A
Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(1):155-63.
-
2000: de Jonge M J; Verweij J; de Bruijn P; Brouwer E; Mathijssen R H; van Alphen R J; de Boer-Dennert M M; Vernillet L; Jacques C; Sparreboom A
Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):195-203.
-
2000: de Jonge M J; Sparreboom A; Planting A S; van der Burg M E; de Boer-Dennert M M; ter Steeg J; Jacques C; Verweij J
Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):187-94.
-
1999: Loos W J; de Bruijn P; van Zuylen L; Verweij J; Nooter K; Stoter G; Sparreboom A
Determination of 5-fluorouracil in microvolumes of human plasma by solvent extraction and high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(2):293-7.
-
1999: Sparreboom A; Loos W J; Nooter K; Stoter G; Verweij J
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.
Journal of chromatography. B, Biomedical sciences and applications 1999;735(1):111-9.
-
1999: Gelderblom H; Verweij J; Brouwer E; Pillay M; de Bruijn P; Nooter K; Stoter G; Sparreboom A
Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(11):1300-5.
-
1999: van Tellingen O; Beijnen J H; Verweij J; Scherrenburg E J; Nooijen W J; Sparreboom A
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2918-24.
-
1999: Sparreboom A; Planting A S; Jewell R C; van der Burg M E; van der Gaast A; de Bruijn P; Loos W J; Nooter K; Chandler L H; Paul E M; Wissel P S; Verweij J
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Anti-cancer drugs 1999;10(8):719-28.
-
1999: Loos W J; Verweij J; Gelderblom H J; de Jonge M J; Brouwer E; Dallaire B K; Sparreboom A
Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans.
Anti-cancer drugs 1999;10(8):705-10.
-
1999: de Jonge M J; Verweij J; Planting A S; van der Burg M E; Stoter G; de Boer-Dennert M M; de Bruijn P; Brouwer E; Vernillet L; Sparreboom A
Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(8):2012-7.
-
1999: de Jonge M J; Punt C J; Gelderblom A H; Loos W J; van Beurden V; Planting A S; van der Burg M E; van Maanen L W; Dallaire B K; Verweij J; Wagener D J; Sparreboom A
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2219-26.
-
1999: Sparreboom A; de Jonge M J; Punt C J; Loos W J; Nooter K; Stoter G; Porro M G; Verweij J
Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(7):816-20.
-
1999: de Jonge M J; Verweij J; Loos W J; Dallaire B K; Sparreboom A
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
Clinical pharmacology and therapeutics 1999;65(5):491-9.
-
1999: Sparreboom A; van Zuylen L; Brouwer E; Loos W J; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
Cancer research 1999;59(7):1454-7.
-
1999: de Bruijn P; de Jonge M J; Verweij J; Loos W J; Nooter K; Stoter G; Sparreboom A
Femtomole quantitation of 7-ethyl-10-hydroxycamptothecine (SN-38) in plasma samples by reversed-phase high-performance liquid chromatography.
Analytical biochemistry 1999;269(1):174-8.
-
1999: Mathijssen R H; van Alphen R J; de Jonge M J; Verweij J; de Bruijn P; Loos W J; Nooter K; Vernillet L; Stoter G; Sparreboom A
Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Anti-cancer drugs 1999;10(1):9-16.
-
1999: de Bruijn P; Verweij J; Loos W J; Kolker H J; Planting A S; Nooter K; Stoter G; Sparreboom A
Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.
Analytical biochemistry 1999;266(2):216-21.
-
1999: Verweij J; Sparreboom A; Nooter K
Mitomycins.
Cancer chemotherapy and biological response modifiers 1999;18():46-58.
-
1999: Gelderblom H A; DE Jonge M J; Sparreboom A; Verweij J
Oral topoisomerase 1 inhibitors in adult patients: present and future.
Investigational new drugs 1999;17(4):401-15.
-
1998: Sparreboom A; de Jonge M J; de Bruijn P; Brouwer E; Nooter K; Loos W J; van Alphen R J; Mathijssen R H; Stoter G; Verweij J
Irinotecan (CPT-11) metabolism and disposition in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(11):2747-54.
-
1998: Sparreboom A; Verweij J; van der Burg M E; Loos W J; Brouwer E; Viganò L; Locatelli A; de Vos A I; Nooter K; Stoter G; Gianni L
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1937-42.
-
1998: Sparreboom A; de Jonge M J; Punt C J; Nooter K; Loos W J; Porro M G; Verweij J
Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(8):1915-9.
-
1998: Brouwer E; Verweij J; Hauns B; Loos W J; Nooter K; Mross K; Stoter G; Sparreboom A
Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
Analytical biochemistry 1998;261(2):198-202.
-
1998: Sparreboom A; de Bruijn P; de Jonge M J; Loos W J; Stoter G; Verweij J; Nooter K
Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):225-35.
-
1998: de Jonge M J; Sparreboom A; Verweij J
The development of combination therapy involving camptothecins: a review of preclinical and early clinical studies.
Cancer treatment reviews 1998;24(3):205-20.
-
1998: Sparreboom A; de Bruijn P; Nooter K; Loos W J; Stoter G; Verweij J
Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;705(1):159-64.
-
1998: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Preclinical pharmacokinetics of paclitaxel and docetaxel.
Anti-cancer drugs 1998;9(1):1-17.
-
1998: Sparreboom A; Loos W J; Verweij J; de Vos A I; van der Burg M E; Stoter G; Nooter K
Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.
Analytical biochemistry 1998;255(2):171-5.
-
1997: de Vos A I; Nooter K; Verweij J; Loos W J; Brouwer E; de Bruijn P; Ruijgrok E J; van der Burg M E; Stoter G; Sparreboom A
Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(11):1145-50.
-
1997: de Bruijn P; Verweij J; Loos W J; Nooter K; Stoter G; Sparreboom A
Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;698(1-2):277-85.
-
1997: Loos W J; Sparreboom A; Verweij J; Nooter K; Stoter G; Schellens J H
Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1997;694(2):435-41.
-
1997: Loos W J; Verweij J; Nooter K; Stoter G; Sparreboom A
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;693(2):437-41.
-
1997: Sparreboom A; van Asperen J; Mayer U; Schinkel A H; Smit J W; Meijer D K; Borst P; Nooijen W J; Beijnen J H; van Tellingen O
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(5):2031-5.
-
1997: van Asperen J; van Tellingen O; Sparreboom A; Schinkel A H; Borst P; Nooijen W J; Beijnen J H
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
British journal of cancer 1997;76(9):1181-3.
-
1996: Sparreboom A; van Tellingen O; Huizing M T; Nooijen W J; Beijnen J H
Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;681(2):355-62.
-
1996: Sparreboom A; Van Tellingen O; Scherrenburg E J; Boesen J J; Huizing M T; Nooijen W J; Versluis C; Beijnen J H
Isolation, purification and biological activity of major docetaxel metabolites from human feces.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(6):655-8.
-
1996: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Cancer research 1996;56(9):2112-5.
-
1996: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Tissue distribution, metabolism and excretion of paclitaxel in mice.
Anti-cancer drugs 1996;7(1):78-86.
-
1995: Huizing M T; Sparreboom A; Rosing H; van Tellingen O; Pinedo H M; Beijnen J H
Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;674(2):261-8.
-
1995: Sparreboom A; van Tellingen O; Nooijen W J; Beijnen J H
Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;664(2):383-91.
-
1995: Sparreboom A; Huizing M T; Boesen J J; Nooijen W J; van Tellingen O; Beijnen J H
Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.
Cancer chemotherapy and pharmacology 1995;36(4):299-304.
-
1994: Shameem M; Imai T; Yoshigae Y; Sparreboom A; Otagiri M
Stereoselective hydrolysis of O-isovaleryl propranolol and its influence on the clearance of propranolol after oral administration.
Journal of pharmaceutical sciences 1994;83(12):1754-7.
Sign-in to see more
